 This study found that 42.3% of patients with chronic myeloid leukemia, CML, in the chronic phase achieved treatment-free remission after stopping their generic imatinent therapy. Patients who had previously achieved molecularly undetectable leukemia, MR5, before stopping their generic imatinent therapy were more likely to achieve treatment-free remission compared to those who did not have MR5. This article was authored by Deepak Goni, Arihant Jain, Charanpreet Singh and others.